Mereo BioPharma to Hold Virtual R&D Day on Thursday, May 13, 2021
LONDON and REDWOOD CITY, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announced it will host a virtual R&D day on Thursday, May 13, 2021 to review the Company’s etigilimab (Anti-TIGIT) program, highlighting studies in ovarian cancer including Clear-cell ovarian cancer, Cervical cancer and Sarcoma. The event will feature a panel of key opinion leaders and will include an update on the Company’s ACTIVATE Phase 1b/2 combination study, and a more detailed review of the recently announced agreement with the Cancer Focus Fund, as well as the planned clinical trial in clear-cell ovarian cancer to be led by The University of Texas MD Anderson Cancer Center.
R&D Day Information
Date: Thursday, May 13, 2021
Time: 11:00 a.m. EDT / 4:00 p.m. GMT
A live audio webcast of the R&D day can be accessed through the Investors section of the Company’s website at www.mereobiopharma.com/investors/results-reports-and-presentations. The event is expected to last approximately two hours. An archived replay of the webcast will be made available on the Company’s website.
About Mereo BioPharma
All of the Company’s forward-looking statements involve known and unknown risks and uncertainties some of which are significant or beyond its control and involve assumptions that could cause actual results to differ materially from the Company’s historical experience and its present expectations or projections. You should carefully consider the foregoing factors and the other risks and uncertainties that affect the Company’s business, including those described in the “Risk Factors” section of its latest Annual Report on Form 20-F, reports on Form 6-K and other documents furnished or filed from time to time by the Company with the SEC. The Company wishes to caution you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise, except to the extent required by law.
Audio ergo sum: Playing with Audio-only Streams in WebRTC and Janus
State of SD-WAN: â€œA View from the C-Suiteâ€
OpenSIPIt - Bringing InterOp Testing to the heart of the Community